Clinical trial
To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to…
NCT00226512 · Hadassah Medical Organization, Other · Withdrawn
Key facts
| NCT number | NCT00226512 |
|---|---|
| Title | To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning |
| Official title | Phase III Trial of a Non-myeloablative Preparative Regimen With Fludarabine and Busulfan With or Without Anti-lymphocyte Antibodies (Campath-1H or ATG) for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation From an HLA Compatible… |
| Lead sponsor | Hadassah Medical Organization, Other |
| Collaborators | Bayer Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Campath-1H /ATG |
| Enrollment | 203 |
| Start date | Jul 1, 2004 |
| First posted | Sep 27, 2005 |
| Last update posted | Apr 8, 2011 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: